SCHEMBL3595662

SCHEMBL3595662

O=C(Cn1ccc2c(-c3ccc(F)cc3)cccc21)NCCNCC1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 7/20 0.46
POLB P06746 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RAB9A P51151 1/20 0.41
P2RX7 Q99572 1/20 0.39
BCHE P06276 2/20 0.39
HTR6 P50406 2/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
CNR2 P34972 1/20 0.37
MAPT P10636 1/20 0.37
NPY5R Q15761 1/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3603572 0.91 MAPT (0.42) GRIN2BSMN1; SMN2RAB9AP2RX7BCHE
SCHEMBL3603868 0.86 ADORA2A (0.41) GRIN2BPOLBSMN1; SMN2RAB9AP2RX7
SCHEMBL3608260 0.85 GRIN2B (0.42) GRIN2BPOLBSMN1; SMN2RAB9AMEN1
SCHEMBL3595659 0.83 MEN1 (0.41) GRIN2BPOLBMEN1KMT2AHCRTR1
SCHEMBL3598310 0.82 NPC1 (0.46) POLBSMN1; SMN2P2RX7BCHEHTR6
SCHEMBL3600291 0.81 GRIN2B (0.55) GRIN2BPOLBSMN1; SMN2RAB9ANPY5R
SCHEMBL3588047 0.81 GRIN2B (0.52) GRIN2BPOLBSMN1; SMN2RAB9ANPY5R
SCHEMBL3606204 0.80 GRIN2B (0.41) GRIN2BPOLBSMN1; SMN2RAB9AMEN1
SCHEMBL3600784 0.79 GRIN2B (0.48) GRIN2BPOLBNPY5R
SCHEMBL3595022 0.78 HSD17B10 (0.55) SMN1; SMN2KMT2ANPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 GRIN2B 2950/4885POLB 4479/4885SMN1; SMN2 4228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.